metaPreg - Primidone (Epilepsy) during pregnancy

Primidone (Epilepsy) updated on 04-22-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.77 [1.33, 5.74]	10%	9 studies	187	156	not evaluable	ROB	4.98 [2.00; .]
Major congenital malformations	2.53 [0.99, 6.48]	21%	7 studies	170	117	not evaluable	ROB	-
Minor congenital malformations	3.46 [0.38, 31.70]	0%	2 studies	12	33	not evaluable	ROB	-
Neural Tube Defects	1.01 [0.06, 17.08]	0%	2 studies	1	41	not evaluable	ROB	-
8 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Small for gestational age (weight)	4.98 [0.31, 81.21]	44%	2 studies	2,424	28	not evaluable	ROB	-
Preterm (< 37 weeks)	25.60 [2.59, 252.91]	-	1 study	5	14	not evaluable	ROB	50.70 [4.62; .]
1 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neuro-developmental disorders (as a whole)	2.15 [0.15, 30.90]	0%	2 studies	4	4	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study